
Early-stage biotech investment: where are we?
Yogan A Patel, Partner at MHA and Head of MHA’s Pharma, Life Science and Med-Tech sector group examines the investment landscape for early-stage biotech companies in the UK and further afield. It is well recognised by both investors and government that the UK has huge strengths in biotechnology. Investment… Read More














